BR112017006113A8 - usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. - Google Patents
usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.Info
- Publication number
- BR112017006113A8 BR112017006113A8 BR112017006113A BR112017006113A BR112017006113A8 BR 112017006113 A8 BR112017006113 A8 BR 112017006113A8 BR 112017006113 A BR112017006113 A BR 112017006113A BR 112017006113 A BR112017006113 A BR 112017006113A BR 112017006113 A8 BR112017006113 A8 BR 112017006113A8
- Authority
- BR
- Brazil
- Prior art keywords
- auristatin
- kits
- pharmaceutical compositions
- dosage forms
- cancer treatment
- Prior art date
Links
- 108010044540 auristatin Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000012823 PI3K/mTOR inhibitor Substances 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
- 229940127084 other anti-cancer agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062192P | 2014-10-10 | 2014-10-10 | |
| PCT/IB2015/057457 WO2016055907A1 (en) | 2014-10-10 | 2015-09-29 | Synergistic auristatin combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017006113A2 BR112017006113A2 (pt) | 2017-12-19 |
| BR112017006113A8 true BR112017006113A8 (pt) | 2018-04-24 |
Family
ID=54288858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017006113A BR112017006113A8 (pt) | 2014-10-10 | 2015-09-29 | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10617670B2 (https=) |
| EP (2) | EP3204005A1 (https=) |
| JP (1) | JP6784668B2 (https=) |
| KR (1) | KR20170058432A (https=) |
| CN (1) | CN107106685A (https=) |
| AU (1) | AU2015329625B2 (https=) |
| BR (1) | BR112017006113A8 (https=) |
| CA (1) | CA2907878A1 (https=) |
| IL (1) | IL251619B (https=) |
| MX (1) | MX2017004580A (https=) |
| RU (1) | RU2717570C2 (https=) |
| WO (1) | WO2016055907A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3019559A4 (en) | 2013-08-22 | 2017-04-05 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
| AU2017240154B2 (en) | 2016-04-01 | 2021-08-12 | Sony Group Corporation | Ultra bright dimeric or polymeric dyes |
| WO2017177065A2 (en) | 2016-04-06 | 2017-10-12 | Sony Corporation | Ultra bright dimeric or polymeric dyes with spacing linker groups |
| EP3455300A1 (en) | 2016-05-11 | 2019-03-20 | Sony Corporation | Ultra bright dimeric or polymeric dyes |
| JP7312929B2 (ja) | 2016-07-29 | 2023-07-24 | ソニーグループ株式会社 | 超明色二量体またはポリマー色素およびその調製のための方法 |
| KR20260011205A (ko) | 2017-10-05 | 2026-01-22 | 소니그룹주식회사 | 프로그램가능한 중합체성 약물 |
| WO2019071153A1 (en) | 2017-10-05 | 2019-04-11 | Sony Corporation | PROGRAMMABLE DENDRITIC MEDICINES |
| WO2019088176A1 (ja) * | 2017-10-31 | 2019-05-09 | 国立大学法人神戸大学 | 抗体薬物複合体効果増強剤 |
| CN111836645A (zh) | 2017-11-16 | 2020-10-27 | 索尼公司 | 可编程的聚合药物 |
| EP4344747A3 (en) * | 2017-11-30 | 2024-07-03 | LadRx Corporation | Albumin-binding prodrugs of auristatin e derivatives |
| US12539334B2 (en) | 2018-01-12 | 2026-02-03 | Sony Group Corporation | Phosphoalkyl polymers comprising biologically active agents |
| EP3737417B1 (en) | 2018-01-12 | 2025-08-27 | Sony Group Corporation | Phosphoalkyl ribose polymers comprising biologically active compounds |
| CN111565756A (zh) | 2018-01-12 | 2020-08-21 | 索尼公司 | 包含生物活性化合物的具有刚性间隔基团的聚合物 |
| KR102742386B1 (ko) | 2018-03-19 | 2024-12-16 | 소니그룹주식회사 | 형광 신호 향상을 위한 2가 금속의 사용 |
| CN118480073A (zh) | 2018-03-21 | 2024-08-13 | 索尼公司 | 具有连接体基团的聚合串联染料 |
| JP7580689B2 (ja) | 2018-06-27 | 2024-11-12 | ソニーグループ株式会社 | デオキシリボースを含むリンカー基を有するポリマー色素 |
| KR20210032434A (ko) | 2018-07-13 | 2021-03-24 | 소니 주식회사 | 유기인산염 단위를 포함하는 백본을 갖는 중합체성 염료 |
| WO2021062176A2 (en) | 2019-09-26 | 2021-04-01 | Sony Corporation | Polymeric tandem dyes with linker groups |
| EP4038081A1 (en) | 2019-09-30 | 2022-08-10 | Sony Group Corporation | Nucleotide probes |
| JP7556194B2 (ja) * | 2019-12-13 | 2024-09-26 | Ｔｏｐｐａｎホールディングス株式会社 | 細胞構造体及びその使用 |
| EP4256078A1 (en) | 2020-12-07 | 2023-10-11 | Sony Group Corporation | Spacing linker group design for brightness enhancement in dimeric or polymeric dyes |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2463615C (en) | 2001-10-30 | 2011-07-26 | Applied Research Systems Ars Holding N.V. | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) |
| US7196090B2 (en) | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
| EP2478912B1 (en) * | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| EP1928912A4 (en) * | 2005-09-07 | 2010-02-24 | Medimmune Inc | EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS |
| US7523124B2 (en) | 2006-06-26 | 2009-04-21 | Nielsen Media Research, Inc. | Methods and apparatus for improving data warehouse performance |
| PT2074122E (pt) | 2006-09-15 | 2011-08-24 | Pfizer Prod Inc | Compostos de pirido(2,3-d)-pirimidinona e sua utilização como inibidores de pi3 |
| CL2008001334A1 (es) * | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| RU2490025C2 (ru) | 2007-10-02 | 2013-08-20 | Чугаи Сейяку Кабусики Кайся | Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6 |
| LT2294072T (lt) | 2008-05-23 | 2017-06-12 | Wyeth Llc | Triazino junginiai, kaip p13 kinazės ir mtor inhibitoriai |
| CA2799540A1 (en) * | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| EP3581206B8 (en) * | 2010-10-22 | 2025-02-19 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| WO2012131527A1 (en) | 2011-04-01 | 2012-10-04 | Wyeth Llc | Antibody-drug conjugates |
| MX2014004991A (es) * | 2011-10-28 | 2014-05-22 | Genentech Inc | Combinaciones terapeuticas y metodos para tratar el melanoma. |
| CN104185477B (zh) * | 2011-11-17 | 2017-05-24 | 辉瑞公司 | 细胞毒性肽及其抗体‑药物缀合物 |
| CA2890571A1 (en) * | 2012-11-07 | 2014-05-15 | Kenneth G. Geles | Anti-notch3 antibodies and antibody-drug conjugates |
| RU2708075C2 (ru) | 2014-04-30 | 2019-12-04 | Пфайзер Инк. | Конъюгаты анти-ртк7 антитело-лекарственное средство |
-
2015
- 2015-09-29 AU AU2015329625A patent/AU2015329625B2/en not_active Ceased
- 2015-09-29 KR KR1020177010980A patent/KR20170058432A/ko not_active Ceased
- 2015-09-29 CN CN201580054253.XA patent/CN107106685A/zh active Pending
- 2015-09-29 BR BR112017006113A patent/BR112017006113A8/pt not_active Application Discontinuation
- 2015-09-29 RU RU2017112048A patent/RU2717570C2/ru active
- 2015-09-29 MX MX2017004580A patent/MX2017004580A/es unknown
- 2015-09-29 EP EP15778051.1A patent/EP3204005A1/en not_active Withdrawn
- 2015-09-29 WO PCT/IB2015/057457 patent/WO2016055907A1/en not_active Ceased
- 2015-09-29 US US15/516,780 patent/US10617670B2/en active Active
- 2015-09-29 JP JP2017518541A patent/JP6784668B2/ja active Active
- 2015-09-29 EP EP19170411.3A patent/EP3549583A1/en not_active Withdrawn
- 2015-10-07 CA CA2907878A patent/CA2907878A1/en active Pending
-
2017
- 2017-04-06 IL IL251619A patent/IL251619B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20180228769A1 (en) | 2018-08-16 |
| RU2017112048A (ru) | 2018-11-15 |
| US10617670B2 (en) | 2020-04-14 |
| CA2907878A1 (en) | 2016-04-10 |
| EP3549583A1 (en) | 2019-10-09 |
| JP2017530983A (ja) | 2017-10-19 |
| MX2017004580A (es) | 2017-06-27 |
| EP3204005A1 (en) | 2017-08-16 |
| AU2015329625B2 (en) | 2018-04-05 |
| RU2017112048A3 (https=) | 2019-05-07 |
| JP6784668B2 (ja) | 2020-11-11 |
| WO2016055907A1 (en) | 2016-04-14 |
| IL251619B (en) | 2020-10-29 |
| IL251619A0 (en) | 2017-06-29 |
| KR20170058432A (ko) | 2017-05-26 |
| AU2015329625A1 (en) | 2017-04-13 |
| CN107106685A (zh) | 2017-08-29 |
| BR112017006113A2 (pt) | 2017-12-19 |
| RU2717570C2 (ru) | 2020-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| CL2018000706A1 (es) | Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer. | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
| BR112016012713A2 (pt) | Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX384403B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| MX383866B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| JOP20200031A1 (ar) | طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة | |
| MX391720B (es) | Terapia combinada para tratar cáncer. | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112017003346B8 (pt) | Derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
| BR112017006299A2 (pt) | derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| BR112016026545A8 (pt) | eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
| TW201613578A (en) | Pharmaceutical combinations | |
| BR112015022846A2 (pt) | uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo | |
| UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| BR112018002520A2 (pt) | Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer | |
| BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |